Lumida
/SBC
⌘K
SBC Medical Group Holdings Inc

SBC Medical Group Holdings Inc

SBC
$3.08USD-2.84%-0.09 today

MARKET CAP

316.8M

P/E (TTM)

7.9x

FWD P/E

6.4x

DAY RANGE

$3 – $3

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

SBC remains in a Stage 4 decline with persistent lower highs and lower lows and price trading below all major EMAs. The medium-term bias is bearish, as the active Post-Capitulation pattern signals only exhaustion without structural repair. Extreme oversold conditions counsel caution, so execution will focus on trimming into rallies toward the 9/20 EMA resistance zone.

  • Underlying revenue +111% YoY and EBITDA +117% YoY ex-fee changes
  • 72% repeat customer rate bolstered by multi-brand segmentation
  • Total revenue fell 9% YoY in Q1 due to fee structure revisions
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

SBC Medical Group Holdings Incorporated (NASDAQ: SBC) is a leading healthcare provider operating a network of aesthetic and non-aesthetic medical facilities in Japan. The company stands out in the competitive aesthetic medical sector by implementing a multi-brand strategy that enables it to appeal to diverse customer demographics. SBC is strategically positioned to capitalize on the rising demand for cosmetic and wellness services, particularly with an aging population and increasing acceptance of aesthetic procedures. Their focus on AI technology integration and diverse treatment offerings, paired with ambitious expansion plans into international markets, positions SBC favorably in the growing healthcare ecosystem.

Bull says

  • Underlying revenue +111% YoY and EBITDA +117% YoY ex-fee changes
  • 72% repeat customer rate bolstered by multi-brand segmentation
  • Ample cash reserves enable M&A and geographic expansion
  • AI integration set to boost productivity and reduce operating costs
  • Aesthetic market growth driven by aging demographics and rising male demand
  • High earnings yield and positive dividend yield attract value investors

Bear says

  • Total revenue fell 9% YoY in Q1 due to fee structure revisions
  • Elevated leverage suggests high debt sensitivity in downturns
  • Intense competition in aesthetic sector threatens market share
  • Negative profitability and growth factors signal margin pressure
  • Low institutional ownership and high volatility imply limited support
  • Poor book-to-price and growth metrics reflect uncertain expansion

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-20-2026neutral

Transcript signals

Read full transcript analysis ›